The Dermatology Digest

JUNE 27, 2024

Eczema is known to take a toll on emotional wellbeing and quality of life, yet 42% of patients with atopic dermatitis (AD) and caregivers of children/teens with eczema have never spoken about mental health with primary eczema care providers, according to new survey results from The National Eczema Association (NEA) in Skin Health and Disease.

Eczema 36

Eczema Dermatitis Therapy Office 36

First Derm

MARCH 8, 2023

Skin-related causes include athlete’s foot, eczema, psoriasis, contact dermatitis, scabies, and fungal infections. Eczema can affect various parts of the body, including the feet. Eczema can affect various parts of the body, including the feet. In severe cases, eczema can cause painful cracks and blisters.

Eczema 52

Eczema Dermatitis Medical Dry Skin 52

The Dermatology Digest

DECEMBER 19, 2023

Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. Brady, MD, PhD, President and Chief Executive Officer of Aldeyra. The primary endpoint of the clinical trial was safety and tolerability.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

MARCH 18, 2024

The National Eczema Association (NEA) has been approved for a $250,000 funding award through the Eugene Washington PCORI Engagement Award Program, an initiative of the Patient-Centered Outcomes Research Institute (PCORI). The PCORI Engagement Award will be directed by Wendy Smith Begolka, MBS, chief strategy officer at NEA and Jessica K.

Eczema 36

Eczema Partnerships Office Clinic 36

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. “It is important to have systemic treatments approved for CHE, both with and without atopic dermatitis.

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies.

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

APRIL 22, 2024

Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% achieved a Validated Investigator Global Assessment (vIGA) score of 0 or 1 after 16 weeks compared to 14.3%

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Fully 80.7% Food and Drug Administration (FDA), expected in Q1 of 2024.

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

DECEMBER 20, 2023

Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

MAY 6, 2024

Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time. Future studies of continuous treatment with IMG-007 in patients with AD could potentially drive more robust efficacy than seen in this proof-of-concept study,” adds Yufang Lu, MD, PhD, Chief Medical Officer of Inmagene.

Safety 36

Safety Therapy Dermatitis Eczema 36

The Dermatology Digest

JULY 14, 2023

While it’s no longer the case that psoriasis is the most common diagnosis among patients getting in-office phototherapy, the treatment option is safe, effective, and should be offered to patients, said Dr. Buzney. “If For eczema, it’s still a very good treatment. Not every patient is a candidate for home phototherapy.

Office 36

Office Eczema Medical Dermatitis 36

US Dermatologt Partners

MAY 29, 2024

Those who have common dermatologic conditions, such as psoriasis and atopic dermatitis (eczema), may also develop white nails. Looking for a dermatologist near your home or office? Dermatology Partners are here to help. Just take a few moments to fill out our online request form to get started working with us.

Treatments 36

Treatments Moisturization Dermatology Medical 36

US Dermatologt Partners

SEPTEMBER 27, 2023

Once the dermatology office receives your request, a team member will be in touch to finalize the details of your visit. If you’re in need of personalized skincare recommendations or treatment, don’t hesitate to get in touch with a local U.S. Dermatology Partners location. Getting started is quick and easy. Dermatology Partners.

Dark Spots 36

Dark Spots Skincare Routine Skin Health Moisturization 36

US Dermatologt Partners

NOVEMBER 22, 2023

Eczema (atopic dermatitis) – skin reddening and itching on the scalp may be a sign of eczema. Allergic reactions – hives, contact dermatitis, rashes, and other forms of allergic reaction can happen in response to hair care products, chemicals, or even sunlight. Folliculitis – a bacterial infection in the hair follicles.

Irritation 36

Irritation Eczema Dermatitis Medical 36

West Lake Dermatology

JUNE 3, 2024

While similar in appearance to facial acne, these unwanted butt bumps and blemishes can be caused by various skin issues beyond typical acne, including folliculitis, keratosis pilaris, boils, and even contact dermatitis or eczema. These blemishes can be unsightly, uncomfortable, and sometimes painful. Is There a Way to Prevent Buttne?

Treatments 36

Treatments Pores Sebum Irritation 36

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. At week 24, 42.3% difference vs. placebo. In the lower dose group, 36.3% difference vs. placebo.

Dermatitis 36

Dermatitis Safety Office Eczema 36

The Dermatology Digest

AUGUST 4, 2023

According to Dr. Richard, today she uses many approaches, including biologics (as monotherapy and in combination), as well as phototherapy, to treat patients with psoriasis, eczema, vitiligo, and a “laundry list” of other skin diseases that respond to light. They extrapolated that across 15 million office visits.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

The Dermatology Digest

FEBRUARY 27, 2025

The nine recipients of the National Eczema Association (NEA) 2024 research grant cycle are Champion Research Grant Encourages proven researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema. NEA has now invested more than$4.4

Eczema 36

Eczema Dermatitis Hospital Office 36

The Dermatology Digest

FEBRUARY 8, 2024

Peter Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, agrees that it is going to be a big year for eczema patients and the doctors who treat them. “I Taking Seb Derm Seriously The U.S.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

FEBRUARY 23, 2023

“So, it is a nice alternative to numbing them up and shaving them off if you’re dealing with a patient that has one in a challenging location or is of an age where they’re not going to tolerate an in-office shave biopsy very well.” Atopic Dermatitis It’s an exciting time in atopic dermatitis (AD), said Dr. Swanson.

Dermatology 36

Dermatology Dermatitis Office Eczema 36

The Dermatology Digest

FEBRUARY 23, 2023

“So, it is a nice alternative to numbing them up and shaving them off if you’re dealing with a patient that has one in a challenging location or is of an age where they’re not going to tolerate an in-office shave biopsy very well.” Atopic Dermatitis It’s an exciting time in atopic dermatitis (AD), said Dr. Swanson.

Dermatology 36

Dermatology Dermatitis Office Eczema 36

The Dermatology Digest

FEBRUARY 24, 2025

improved atopic dermatitis (AD) across all primary and secondary efficacy endpoints, with significant improvement as early as Week 1 on multiple efficacy endpoints in kids aged 2 to 5, according to the INTEGUMENT-PED Trial. The post Roflumilast Cream 0.05% Performs Well in Pediatric Eczema appeared first on The Dermatology Digest.

Eczema 67

Eczema Dermatitis Safety Dermatology 67

The Dermatology Digest

OCTOBER 29, 2024

Rezpegaldesleukin showed durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes in patients with atopic dermatitis (AD) and psoriasis (PsO), according to two Phase 1b studies in Nature Communications. Chief Research & Development Officer at Nektar.

Dermatitis 36

Dermatitis Clinic Sustainability Eczema 36

US Dermatologt Partners

DECEMBER 25, 2024

These include nipple eczema, inverse psoriasis, and irritant dermatitis, which he notes is colloquially called joggers nipple. These conditions, are far more likely to present to the dermatologists office than metastatic breast cancer with cutaneous involvement, he says.

Dermatology 41

Dermatology Management Therapy Irritation 41